biotech / news / / The Boston Globe
Biogen Inc. said it will continue development of its experimental Alzheimer's drug.
Biogen's diranersen targets tau protein buildup inside neurons using antisense oligonucleotide technology.
KEY POINTS
- Although the phase II trial missed its primary goal, Biogen saw slower disease progression at all dose levels.
- Patients receiving the lowest dose of diranersen experienced the greatest cognitive benefit in the study.
- Biogen will advance diranersen to a late-stage trial, potentially combining it with amyloid-targeting drugs.
COMPANIES
Summarized by Newsio from The Boston Globe. How we summarize →